Concerns & Risks -- 4/10
A score of 4 reflects significant risks that outweigh near-term catalysts. China at ~28% of
revenue is the worst exposure among U.S. semi equipment peers, amplified by a $252M BIS
settlement and bipartisan Congressional momentum toward blanket equipment bans. Revenue has
turned YoY negative in the last two quarters, and the GAA/packaging catalysts that underpin
the bull case are forward-looking and not yet visible in reported numbers. The valuation
discount to peers exists because the market correctly prices these risks.
Weight: 15%
EV/EBITDA (NTM)
~20x
Discount to peer avg ~27x
P/E (NTM)
28.9x
Peer avg ~33x; discount narrows on P/E
China Revenue %
~28-30%
Highest among U.S. semi equipment peers
BIS Settlement
$252M
56 unauthorized export violations (2021-22)
Valuation snapshot
| Metric | Value | Source / Note |
|---|---|---|
| Stock Price | $348.47 | As of scoring date |
| EV / EBITDA (NTM) | ~20x | Peer avg ~27x (ASML ~30x, LRCX ~38x, KLAC ~25x, TEL ~15x) |
| P/E (NTM) | 28.9x | Peer avg ~33x (ASML 35x, KLAC 32x, LRCX 36x, TEL 22x) |
| EV / Revenue (NTM) | ~8.6x | Roughly in-line with peer avg ~10x |
| FY2026E Revenue | $32.05B | Consensus (28 analysts, StockAnalysis) +13.0% YoY |
| FY2026E EPS (Non-GAAP) | $11.21 | +29.5% YoY vs FY2025 $8.66 |
| FY2027E EPS (Non-GAAP) | $14.26 | +27.2% YoY; implies ~24x fwd P/E on FY27E |
| China Revenue (FQ1 2026) | $2,095M | 29.9% of total revenue; ranged 25-35% over last 5 quarters |
| FCF (FY2025) | $5,698M | Down -23.9% YoY on EPIC Center CapEx ($2.3B total) |
| Share Buybacks (FY2025) | $4.9B | $14.8B remaining authorization; shares 799M (-5.7% over 12Q) |
Peer valuation comparison
| Company | Ticker | EV/EBITDA (NTM) | Fwd P/E (NTM) | Key Overlap |
|---|---|---|---|---|
| Applied Materials | AMAT | ~20x | 28.9x | Deposition, CMP, implant, PVD, etch |
| ASML | ASML | ~30x | ~35x | Lithography monopoly, WFE leader |
| Lam Research | LRCX | ~38x | ~36x | Etch #1, deposition #2 |
| KLA Corp | KLAC | ~25x | ~32x | Process control, inspection |
| Tokyo Electron | TEL | ~15x | ~22x | Coater/developer, etch, deposition |
| Peer Average (ex-AMAT) | ~27x | ~33x | AMAT at ~26% EV/EBITDA discount, ~12% P/E discount |
AMAT trades at a meaningful discount to peers on EV/EBITDA and P/E. This discount exists
because the market is pricing in China regulatory risk -- not despite it. The discount narrows
on EV/Revenue (~8.6x vs ~10x peer avg), reflecting lower margin expectations.
China exposure -- critical risk
| Metric | FQ1 2025 | FQ2 2025 | FQ3 2025 | FQ4 2025 | FQ1 2026 |
|---|---|---|---|---|---|
| China Rev ($M) | $2,243 | $1,774 | $2,548 | $1,964 | $2,095 |
| China % of Total | 31.3% | 25.0% | 34.9% | 28.9% | 29.9% |
Regulatory escalation path: $600-710M FY2026 revenue at risk from new export
restrictions. Entity-list expansion doubled restricted China WFE market from ~10% to >20%.
Congressional push for blanket China equipment ban could remove $1-2B+ revenue. CFO Hill
acknowledged they have been "wrong for 2 years in a row forecasting digestion" in China --
implying potential upside asymmetry from a large pending license backlog. Management expects
normalization toward mid-20s%.
Key catalysts (bull case)
| # | Catalyst | Detail | Confidence |
|---|---|---|---|
| 1 | GAA ramp (>50% incremental share) | 300K wafer starts at full scale (only ~100K installed). >50% share capture across 4 technology nodes. Semi Systems guided >20% growth in CY2026. | High |
| 2 | Advanced packaging doubling to $3B+ | Hybrid bonding, TSV, HBM. Not broadly modeled by Street. Backed by real CapEx (EPIC Center, Singapore R&D center). | High |
| 3 | AI/HPC WFE supercycle | WFE TAM growing from $115.7B (2025E) to ~$156B (2027E). >20% equipment growth driven by AI demand. | Med-High |
| 4 | Backside power delivery | Introduces new process steps where AMAT claims >50% served share. CY2027-2028 timing. | Med-High |
| 5 | NAND recovery | NAND WFE at cycle trough. Recovery would provide incremental revenue tailwind. | Medium |
Key risks (bear case)
| # | Risk | Severity | Detail |
|---|---|---|---|
| 1 | Further China export controls / blanket ban | HIGH | ~28% of revenue at risk. $600-710M already identified for FY2026. Congressional push could remove $1-2B+. Binary regulatory tail risk. |
| 2 | $252M BIS settlement overhang | HIGH | 56 unauthorized export violations (2021-2022). Settlement realized, but signals heightened regulatory scrutiny on AMAT specifically. |
| 3 | Revenue deceleration / YoY negative | HIGH | FQ4 2025 rev -3.5% YoY, FQ1 2026 -2.1% YoY. EPS flat YoY. Two consecutive quarters of negative growth after six years of annual increases. |
| 4 | Tariff / trade war escalation | MEDIUM | Broader trade war could compress WFE spending and delay customer capacity decisions beyond China-specific restrictions. |
| 5 | WFE cycle peak in CY2026 | MEDIUM | If WFE peaks in CY2026 rather than growing through CY2027-28, the consensus EPS ramp ($11.21 to $14.26) breaks down. |
| 6 | Gross margin expansion fading | MEDIUM | GM YoY expansion decelerated from +164bps to +20bps over 5 quarters. Management cites 48% as baseline. Pricing gains plateauing. |
| 7 | FCF decline on EPIC Center CapEx | LOW-MED | FCF down -24% in FY2025 to $5.7B. CapEx normalizing (FQ1 2026 $646M vs FQ4 2025 $785M). Early recovery signs mitigate severity. |
Scenario analysis
| Scenario | FY27E NG EPS | Implied P/E | Probability |
|---|---|---|---|
| Bull -- GAA ramp + packaging + China stabilizes | $15.00+ | ~23x | 20% |
| Base -- consensus plays out | $14.26 | ~24x | 45% |
| Bear -- China ban + WFE peak + margin compression | ~$10.00 | ~35x | 35% |
The asymmetry skews negative. The bear case carries 35% probability with
binary regulatory risk that could remove $1-2B+ of revenue in a single policy change.
The bull case requires GAA ramp confirmation, China stabilization, and WFE cycle extension --
all of which are forward-looking and not yet in reported numbers. The peer discount is
warranted until China regulatory clarity improves or revenue YoY growth turns positive
(expected H2 CY2026).
Score rationale
Score of 4/10 reflects significant risks that currently outweigh the secular catalysts.
Negatives: China at ~28% of revenue is worst-in-class U.S. semi equipment exposure, amplified by $252M BIS settlement and bipartisan ban momentum (-). Revenue turned YoY negative in last two quarters after six consecutive years of annual growth (-). Gross margin expansion decelerating rapidly (+164bps to +20bps over 5 quarters) (-). FCF down -24% in FY2025 on EPIC Center investment (-). EPS growth flatlined at 0% YoY in FQ1 2026 (-). Consensus embeds +29.5% EPS growth in FY2026E and +27.2% in FY2027E -- the catalysts are priced into estimates, not hidden (-).
Positives: Valuation discount to peers on EV/EBITDA (~20x vs ~27x) provides some cushion (+). Dominant oligopoly positions in 4+ sub-segments with extreme switching costs (+). 91% management promise hit rate with 5 consecutive EPS beats (+). GAA, packaging, and backside power delivery are real secular drivers (+). Early FCF recovery signs in FQ1 2026 (+91% YoY) as CapEx normalizes (+).
Net: The discount exists for good reason. Re-evaluate when: (1) revenue YoY growth turns positive (expected H2 CY2026), (2) China regulatory clarity improves, or (3) valuation discount widens to >25% below peers on P/E.
Data sourced from Daloopa, StockAnalysis, and earnings transcripts.